LU92195I2 - Aflibercept (EYLEA-ZALTRAP) - Google Patents

Aflibercept (EYLEA-ZALTRAP)

Info

Publication number
LU92195I2
LU92195I2 LU92195C LU92195C LU92195I2 LU 92195 I2 LU92195 I2 LU 92195I2 LU 92195 C LU92195 C LU 92195C LU 92195 C LU92195 C LU 92195C LU 92195 I2 LU92195 I2 LU 92195I2
Authority
LU
Luxembourg
Prior art keywords
zaltrap
eylea
aflibercept
macular degeneration
diabetic retinopathy
Prior art date
Application number
LU92195C
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22480568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92195(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of LU92195I2 publication Critical patent/LU92195I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
LU92195C 1999-06-08 2013-05-14 Aflibercept (EYLEA-ZALTRAP) LU92195I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13813399P 1999-06-08 1999-06-08

Publications (1)

Publication Number Publication Date
LU92195I2 true LU92195I2 (fr) 2013-07-15

Family

ID=22480568

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92195C LU92195I2 (fr) 1999-06-08 2013-05-14 Aflibercept (EYLEA-ZALTRAP)

Country Status (33)

Country Link
EP (2) EP1544299B1 (fr)
JP (2) JP4723140B2 (fr)
KR (1) KR100659477B1 (fr)
CN (3) CN100523187C (fr)
AT (2) ATE293164T1 (fr)
AU (2) AU779303B2 (fr)
BE (1) BE2013C029I2 (fr)
BR (2) BR0011407A (fr)
CA (1) CA2376379C (fr)
CY (2) CY1108883T1 (fr)
CZ (2) CZ303656B6 (fr)
DE (2) DE60041159D1 (fr)
DK (2) DK1544299T3 (fr)
ES (2) ES2319305T3 (fr)
FR (1) FR13C0028I2 (fr)
HK (3) HK1043388A1 (fr)
HR (1) HRP20010908B1 (fr)
HU (3) HU229156B1 (fr)
IL (3) IL146890A0 (fr)
LT (1) LTC1183353I2 (fr)
LU (1) LU92195I2 (fr)
ME (2) MEP3208A (fr)
MX (1) MXPA01012630A (fr)
NO (4) NO330775B1 (fr)
NZ (1) NZ515913A (fr)
PL (1) PL208247B1 (fr)
PT (2) PT1183353E (fr)
RS (1) RS50073B (fr)
RU (1) RU2265661C2 (fr)
SK (1) SK287332B6 (fr)
UA (1) UA74146C2 (fr)
WO (1) WO2000075319A1 (fr)
ZA (1) ZA200110068B (fr)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
JP4669984B2 (ja) 2001-01-19 2011-04-13 ベジェニクス リミテッド 腫瘍画像化のターゲットとしてのＦ１ｔ４（ＶＥＧＦＲ−３）および抗腫瘍療法
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
US8183350B2 (en) 2002-05-04 2012-05-22 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
US7052691B2 (en) 2003-03-28 2006-05-30 Regeneron Pharmaceuticals, Inc. Methods of treating diabetes by blocking VEGF-mediated activity
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
AU2004247025B8 (en) * 2003-05-16 2011-06-30 Acorda Therapeutics, Inc. Fusion proteins for the treatment of CNS
EP2460881B1 (fr) 2003-05-16 2017-05-03 Acorda Therapeutics, Inc. Mutants de degradation du proteoglycane pour le traitement du systeme nerveux central
WO2004106378A2 (fr) * 2003-05-28 2004-12-09 Regeneron Pharmaceuticals, Inc. Methode de traitement du rejet de greffon corneen
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
JP2006527198A (ja) * 2003-06-06 2006-11-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆインヒビターを用いる腫瘍退縮方法
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
CA2534197A1 (fr) * 2003-08-06 2005-02-24 Thomas Jefferson University Utilisation d'un antagoniste des vegf en combinaison avec une radiotherapie
MXPA06013345A (es) 2004-05-18 2008-10-31 Acorda Therapeutics Inc Metodos para purificar condrointinasa y sus formulaciones estables.
US7750138B2 (en) * 2004-06-08 2010-07-06 Chengdu Kanghong Biotechnologies Co. Ltd. Angiogenesis-inhibiting chimeric protein and the use
CN101102786A (zh) 2004-06-10 2008-01-09 瑞泽恩制药公司 施用并利用vegf抑制剂治疗人类癌症的方法
EP1755645A2 (fr) * 2004-06-18 2007-02-28 Regeneron Pharmaceuticals, Inc. Methode d'administration d'inhibiteurs de vegf pour le traitement d'un epanchement pleural malin
AU2005267741A1 (en) 2004-07-30 2006-02-09 Regeneron Pharmaceuticals, Inc. Methods of treating type I diabetes by blocking VEGF-mediated activity
BRPI0515264B1 (pt) * 2004-09-13 2018-12-18 Genzyme Corp proteína de fusão de acordo com fórmula x-y-z, composição, molécula de ácido nucleico, seus usos e método de multimerização de um polipeptídeo x
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
AU2006214658A1 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
PT2586459T (pt) 2005-03-25 2017-07-25 Regeneron Pharma Formulações antagonistas de fcev
WO2007038548A2 (fr) 2005-09-26 2007-04-05 Acorda Therapeutics, Inc. Compositions et procedes d'utilisation de mutants des chondroitinases abci
ES2400666T5 (es) † 2005-12-16 2016-03-10 Regeneron Pharmaceuticals, Inc. Uso terapéutico de un antagonista de DII4 y un inhibidor de VEGF para inhibir el crecimiento tumoral
FR2895258B1 (fr) 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
CN100502945C (zh) * 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
EP3753548A1 (fr) 2006-06-16 2020-12-23 Regeneron Pharmaceuticals, Inc. Formulations antagonistes vegf appropriées pour l'administration intravitréenne
EP2066694B1 (fr) 2006-09-29 2015-11-04 Oncomed Pharmaceuticals, Inc. Compositions et procédés permettant de diagnostiquer et de traiter le cancer
WO2008045970A2 (fr) 2006-10-10 2008-04-17 Acorda Therapeutics, Inc. Compositions et procédés d'utilisation de mutants des chondroïtinases abci
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN101575379B (zh) * 2008-05-09 2012-05-30 上海抗体药物国家工程研究中心有限公司 可溶性vegfr双功能融合受体、其制备方法及用途
RU2550258C2 (ru) 2008-11-03 2015-05-10 Молекьюлар Партнерс Аг Связывающие белки, ингибирующие взаимодействия vegf-a рецептора
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
ES2700450T3 (es) 2009-10-16 2019-02-15 Oncomed Pharm Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
LT2601214T (lt) 2010-08-06 2018-02-26 Genzyme Corporation Vegf antagonistų kompozicijos ir jų panaudojimas
US20140080153A1 (en) * 2011-01-07 2014-03-20 Chugai Seiyaku Kabushiki Kaisha Method for improving physical properties of antibody
CA2824422A1 (fr) 2011-01-13 2012-07-19 Regeneron Pharmaceuticals, Inc. Utilisation d'antagoniste de vegf pour traiter des troubles oculaires angiogeniques
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
KR101397088B1 (ko) 2011-06-10 2014-05-19 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
BR112014013205A2 (pt) 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
CN103304668B (zh) * 2012-03-12 2015-10-28 江苏健德生物药业有限公司 Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
EP2846836B1 (fr) 2012-05-07 2019-08-14 Allergan, Inc. Procédé de traitement d'amd chez des patients souffrant d'un état réfractaire à la thérapie anti-vegf
WO2014006113A1 (fr) 2012-07-03 2014-01-09 Sanofi Procédé de traitement du cancer par quantités efficaces d'aflibercept
AR093445A1 (es) 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4
NZ710658A (en) 2013-02-18 2019-12-20 Vegenics Pty Ltd Ligand binding molecules and uses thereof
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CN104193828B (zh) * 2013-09-12 2017-04-05 北京韩美药品有限公司 同时阻断her2和vegfr信号通路的重组融合蛋白
CA2927012A1 (fr) 2013-11-05 2015-05-14 Allergan, Inc. Procede de traitement d'etats de sante de l'oeil par un darpin anti-vegf
KR20170003973A (ko) 2014-05-12 2017-01-10 포르미콘 아게 Ｖｅｇｆ 안타고니스트를 포함하는 사전충전형 플라스틱제 주사기
LT3170005T (lt) 2014-07-18 2019-07-10 Sanofi Paciento, įtariamo, kad serga vėžiu, gydymo afliberceptu rezultato prognozavimo būdas
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
PT3230316T (pt) 2014-12-11 2022-02-24 Bayer Healthcare Llc Ratamento de degenerescência macular relacionada com a idade com uma pequena lesão de neovascularização coroideia ativa
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
TW202330904A (zh) 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
WO2017046140A1 (fr) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Régimes de traitement de dr et rvo en fonction de l'étendue de l'ischémie rétinienne
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
WO2017065559A1 (fr) 2015-10-15 2017-04-20 (주)알테오젠 Procédé de production de protéine de fusion présentant un domaine fc d'igg
MX2018006092A (es) 2015-11-18 2019-01-31 Formycon Ag Envase farmacéutico precargado que comprende una formulación líquida de un antagonista del vegf.
JP2019501687A (ja) 2015-11-18 2019-01-24 フォーマイコン アーゲーＦｏｒｍｙｃｏｎ Ａｇ Ｖｅｇｆ拮抗薬を収容したプレフィルドプラスチックシリンジ
US11654046B2 (en) 2015-11-18 2023-05-23 Sio2 Medical Products, Inc. Pharmaceutical package for ophthalmic formulations
EP3377101A4 (fr) * 2015-11-19 2019-08-07 Zhuhai Tairuishang Biopharm Ltd. Méthodes et compositions de liaison de vegf
CN108474039B (zh) 2015-12-03 2022-06-07 雷杰纳荣制药公司 抗vegf剂在制备用于治疗新生血管性年龄相关性黄斑变性患者的药物中的用途
CA3011638C (fr) 2016-01-26 2023-01-10 Formycon Ag Formulation liquide d'un antagoniste du vegf
EP3527225A4 (fr) 2016-10-12 2020-06-10 Daiichi Sankyo Company, Limited Composition contenant un anticorps anti-robo4 et un autre agent
US11135266B2 (en) 2016-11-21 2021-10-05 Just-Evotec Biologics, Inc. Aflibercept formulations and uses thereof
WO2018215580A1 (fr) 2017-05-24 2018-11-29 Formycon Ag Procédé de stérilisation de seringues en plastique pré-remplies contenant un antagoniste du vegf
WO2018217995A1 (fr) 2017-05-24 2018-11-29 Formycon Ag Conditionnements pharmaceutiques pré-remplis stérilisables comprenant une formulation liquide d'un antagoniste du vegf
EP3630062A2 (fr) 2017-05-24 2020-04-08 SiO2 Medical Products, Inc. Conditionnement pharmaceutique stérilisable pour formulations ophtalmiques
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2019020777A1 (fr) 2017-07-26 2019-01-31 Formycon Ag Formulation liquide d'un antagoniste du vegf
CA3067735A1 (fr) 2017-08-17 2019-02-21 Just Biotherapeutics, Inc. Procede de purification de proteine glycosylee a partir de galectines et d'autres contaminants de cellules hotes
CN111356471A (zh) 2017-11-20 2020-06-30 济世发展生物药业有限公司 包含赖氨酸盐作为张力调节剂的阿柏西普制剂及其用途
CR20200282A (es) 2017-11-27 2021-02-18 4D Molecular Therapeutics Inc Cápsides variantes de virus adenoasociados y su uso para inhibir la angiogénesis
SG11202004268PA (en) 2017-11-30 2020-06-29 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders
EA039731B1 (ru) * 2017-12-13 2022-03-04 Ридженерон Фармасьютикалз, Инк. Устройства и системы для управления опорой слоя сорбента хроматографической колонки и связанные с ними способы
EA202091786A1 (ru) * 2018-01-26 2020-10-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Способы и композиции для лечения ангиогенных расстройств с применением агентов против фрэс
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
CA3099551A1 (fr) 2018-05-10 2019-11-14 Regeneron Pharmaceuticals, Inc. Formulations contenant des proteines de fusion du recepteur vegf a haute concentration
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN111378044B (zh) 2018-12-28 2022-07-15 长春金赛药业有限责任公司 抗体融合蛋白、制备方法及其应用
WO2020229584A1 (fr) 2019-05-16 2020-11-19 Formycon Ag Procédé de réduction de l'oxydation de la méthionine dans des protéines recombinantes
TW202123988A (zh) 2019-09-03 2021-07-01 美商安進公司 用於藥物遞送之注入裝置及用於注入裝置之包裝物
AU2020348947A1 (en) 2019-09-16 2022-03-10 Amgen Inc. Method for external sterilization of drug delivery device
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
JP2023502501A (ja) 2019-11-25 2023-01-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 眼内血管新生のための長時間作用型ｖｅｇｆ阻害剤
IL302538A (en) 2019-12-06 2023-07-01 Regeneron Pharma Anti-VEGF protein preparations and methods for their production
EP4069264A1 (fr) 2019-12-06 2022-10-12 Regeneron Pharmaceuticals, Inc. Mini-pièges de vegf et leurs procédés d'utilisation
WO2021173603A1 (fr) 2020-02-24 2021-09-02 Amgen Inc. Récipients et systèmes destinés à être utilisés pendant la stérilisation externe de dispositifs d'administration de médicament
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
EP4145456A1 (fr) 2021-09-06 2023-03-08 Bayer AG Prédiction d'un changement relatif à un fluide maculaire
WO2023092324A1 (fr) 2021-11-24 2023-06-01 苏州光度生物科技有限公司 Molécule de liaison de ligand multispécifique et son utilisation
WO2024029876A1 (fr) * 2022-08-02 2024-02-08 주식회사 파노로스바이오사이언스 Protéine de fusion modifiée et son utilisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production

Also Published As

Publication number Publication date
DE60019415D1 (de) 2005-05-19
CN1369009A (zh) 2002-09-11
ATE417928T1 (de) 2009-01-15
EP1183353A1 (fr) 2002-03-06
NO2013010I1 (no) 2013-06-17
SK17522001A3 (sk) 2003-04-01
BRPI0011407B1 (pt) 2018-09-25
NO2022060I1 (no) 2022-12-21
LTPA2013009I1 (lt) 2013-06-25
BR0011407A (pt) 2002-04-02
KR20020019070A (ko) 2002-03-09
HRP20010908B1 (en) 2006-05-31
PT1183353E (pt) 2005-06-30
WO2000075319A1 (fr) 2000-12-14
CZ303656B6 (cs) 2013-01-30
HUS1300052I1 (hu) 2016-08-29
FR13C0028I1 (fr) 2013-06-14
FR13C0028I2 (fr) 2014-05-16
HRP20010908A2 (en) 2005-04-30
CZ302689B6 (cs) 2011-09-07
ES2319305T3 (es) 2009-05-06
DE60041159D1 (de) 2009-01-29
AU2005201365B2 (en) 2007-08-09
PL208247B1 (pl) 2011-04-29
NZ515913A (en) 2004-01-30
AU779303B2 (en) 2005-01-13
BE2013C029I2 (fr) 2019-03-06
HK1132653A1 (en) 2010-03-05
ATE293164T1 (de) 2005-04-15
RS50073B (sr) 2009-01-22
CA2376379A1 (fr) 2000-12-14
SK287332B6 (sk) 2010-07-07
PT1544299E (pt) 2009-03-18
NO20016036D0 (no) 2001-12-10
CN101433715A (zh) 2009-05-20
HK1043388A1 (en) 2002-09-13
ES2237429T3 (es) 2005-08-01
CY1108883T1 (el) 2014-07-02
HK1185798A1 (en) 2014-02-28
JP4723140B2 (ja) 2011-07-13
ME00024B (fr) 2010-02-10
NO20100656L (no) 2002-02-08
YU86901A (sh) 2004-05-12
AU2005201365A1 (en) 2005-04-28
PL352246A1 (en) 2003-08-11
CN103349781A (zh) 2013-10-16
HUP0201515A3 (en) 2004-12-28
BRPI0011407B8 (pt) 2021-05-25
AU5040400A (en) 2000-12-28
DK1183353T3 (da) 2005-08-08
JP2011024595A (ja) 2011-02-10
NO332559B1 (no) 2012-10-29
EP1183353B1 (fr) 2005-04-13
JP2003501089A (ja) 2003-01-14
HUP0201515A2 (en) 2002-08-28
CA2376379C (fr) 2007-08-07
CZ20014387A3 (cs) 2002-10-16
CN100523187C (zh) 2009-08-05
NO20016036L (no) 2002-02-08
DK1544299T3 (da) 2009-03-23
HU229156B1 (en) 2013-09-30
IL146890A (en) 2008-07-08
CN103349781B (zh) 2015-04-01
DE60019415T2 (de) 2006-03-09
MEP3208A (xx) 2010-02-10
ZA200110068B (en) 2002-12-06
IL190234A0 (en) 2008-11-03
CY2013019I2 (el) 2015-11-04
EP1544299A1 (fr) 2005-06-22
JP5273746B2 (ja) 2013-08-28
CN101433715B (zh) 2013-04-17
KR100659477B1 (ko) 2006-12-20
EP1544299B1 (fr) 2008-12-17
CY2013019I1 (el) 2015-11-04
RU2265661C2 (ru) 2005-12-10
IL146890A0 (en) 2002-08-14
HU230159B1 (hu) 2015-09-28
NO2013010I2 (no) 2013-05-15
MXPA01012630A (es) 2002-07-22
LTC1183353I2 (lt) 2023-02-27
UA74146C2 (uk) 2005-11-15
NO330775B1 (no) 2011-07-11

Similar Documents

Publication Publication Date Title
LU92195I2 (fr) Aflibercept (EYLEA-ZALTRAP)
MXPA02001911A (es) Anticuerpos ctla-4 humanos y sus usos.
ATE396738T1 (de) Verwendung von glp-2-peptiden
DE60137876D1 (de) Analoge des Glucagon-ähnlichen Peptids-1
DE60118921D1 (de) Verfahren und Zusammensetzungen unter Verwendung von Chinazolinonen
DE60042066D1 (de) Chimärische dr4 antikörper und ihre verwendung
IL181695A0 (en) Methods for cultivating cells and propagating viruses
NO992916D0 (no) Fosfodiesterase 8A
PL1694354T3 (pl) Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
ATE319819T1 (de) Humane hirn-spezifische carboxypeptidase b
BR9909473B1 (pt) composição herbicida, e, processo para controlar ervas daninhas.